FibroGen Q1 net loss narrows to $16.8M; China sale consideration raised to ~$185M

KYNTRA BIO, INC.

2025-Q1 EPS reported $0.05 revenue$2,739,000

Total revenue from continuing ops fell to $2.7M from $25.4M YoY; net loss improved to $16.8M ($0.16/sh) from $49.0M.
Sale of FibroGen China to AstraZeneca now expected total consideration ~$185M (enterprise $85M + net cash ~$100M); close in 3Q-2025.
Upon China sale close, cash runway extended into 2H 2027; Morgan Stanley term loan to be repaid.
Phase 2 monotherapy trial of FG-3246 (CD46 ADC) in mCRPC expected to start 3Q-2025; topline combo data from UCSF study due 4Q-2025.
Filed Type-C meeting request with FDA for roxadustat in LR-MDS anemia; feedback expected in 3Q-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.